| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 81.16% | 81.62% | 88.51% | 88.48% | 89.24% | 89.43% | 88.44% |
| Operating Margin | -157.14% | -132.54% | -116.98% | -61.82% | -53.66% | -42.25% | -57.44% |
| EBITDA Margin | -144.00% | -121.37% | -106.88% | -55.72% | -49.46% | -38.25% | -54.61% |
| Net Margin | -135.14% | -106.29% | -91.85% | -53.25% | -56.30% | -45.15% | -59.64% |
| Current Ratio | 8.30 | 10.88 | 10.65 | 16.35 | 17.32 | 3.90 | — |
| Quick Ratio | 7.77 | 10.32 | 9.97 | 15.80 | 16.98 | 3.52 | — |
| Debt / Equity | — | — | — | — | — | — | — |
| ROE | -26.02% | -19.91% | -16.33% | -9.28% | -7.26% | -35.56% | — |
| ROA | -22.04% | -17.14% | -14.14% | -8.22% | -6.72% | -22.82% | — |
| Asset Turnover | 0.16 | 0.16 | 0.15 | 0.15 | 0.12 | 0.51 | — |
| Book Value / Share | 1.61 | 1.97 | 2.25 | 2.50 | 2.90 | 0.48 | — |
MaxCyte, Inc. is a commercial cell-engineering company that provides enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics. Its proprietary Flow Electroporation platform and ExPERT instrument portfolio, including ExPERT ATx for small to medium scale transfection, ExPERT STx for protein production and drug development, ExPERT GTx for large scale therapeutic applications, and ExPERT VLx for very large volume cell-engineering, deliver high transfection efficiency, cell viability, and scalability. The company also offers disposable processing assemblies, electroporation buffers, software protocols, and SeQure DX services for on-target and off-target editing assessments. MaxCyte generates revenue through sales of instruments, consumables, licenses, and its Strategic Platform License program, which grants partners non-exclusive rights for research, clinical, and commercial use, including milestone payments and royalties. These technologies support diverse cell types and payloads in cell and gene therapies for cancer, autoimmune diseases, and other areas, serving pharmaceutical and biotechnology companies worldwide. Founded in 1998 and headquartered in Rockville, Maryland, MaxCyte plays a key role in the biotechnology sector by facilitating precise, efficient, and GMP-ready cell engineering.